News
Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...
TipRanks on MSN13h
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...
Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback